Arch Oncology
- Total Funding$155 M
OverviewSuggest Edit
Arch Oncology is a clinical-stage immuno-oncology company focused on the discovery and development of antibody therapies for the treatment of patients with cancer. The Company's lead product candidate AO-176 is in Phase 1 clinical trial for the treatment of patients with select solid tumors. In addition, Arch Oncology is advancing pipeline programs, including anti-signal regulatory protein (SIRP) antibodies.
| Type | Private | |
| Founded | 2006 | |
| HQ | Brisbane, CA, US | Map |
| Website | archoncology.com |
Recent NewsAll News
- Arch Oncology Receives U.S. FDA Orphan Drug Designation for AO-176, a Next-Generation Anti-CD47 IgG2 Antibody, for the Treatment of Multiple Myeloma
- Arch Oncology Strengthens Medical and Clinical Leadership Teams with Key Appointments
- Arch Oncology Secures $105 Million Series C Financing
- Arch Oncology Presents New Preclinical T-ALL Data on Highly-differentiated Anti-CD47 Antibody AO-176 at AACR 2021
Latest Updates
| Employees (est.) (Aug 2022) | 43 | |
| Cybersecurity rating | A | More |
Key People/Management at Arch Oncology
John McKearn
Chairman
Daniel Pereira
Chief Scientific Officer
Arun Kashyap
Vice President, Research
Vicki Sung
Vice President, Translational Medicine
Arch Oncology Office Locations
Arch Oncology has offices in Brisbane and St. Louis
Brisbane, CA, US (HQ)
2000 Sierra Point Pkwy #700Brisbane
St. Louis, MO, US
4340 Duncan Ave #301
Arch Oncology Financials and Metrics
Summary Metrics
Founding Date | 2006 |
Arch Oncology total Funding | $155 m |
Arch Oncology latest funding size | $105 m |
Time since last funding | a year ago |
Arch Oncology investors | Roche Venture Fund, RiverVest, Adage Capital Management, 3x5 Special Opportunity Fund, Eventide Asset Management, Cowen Healthcare Investments, RiverVest Venture Partners, Lightchain, 3×5 Partners, Point72 Asset Management, Avego Healthcare Capital, FMB Research, Broadfin Holdings |
Arch Oncology's latest funding round in May 2021 was reported to be $105 m. In total, Arch Oncology has raised $155 m
Arch Oncology Cybersecurity Score
Arch Oncology Online and Social Media Presence
Arch Oncology's Trends
Arch Oncology News and Updates
January 21, 2022
Arch Oncology Receives U.S. FDA Orphan Drug Designation for AO-176, a Next-Generation Anti-CD47 IgG2 Antibody, for the Treatment of Multiple Myeloma
BRISBANE, Calif. and ST. LOUIS, Jan. 21, 2022 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 biologic therapies, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation…
August 02, 2021
Arch Oncology Strengthens Medical and Clinical Leadership Teams with Key Appointments
– Seasoned oncology leaders Louie Naumovski, M.D., Ph.D., appointed as Chief Medical Officer; Amit Agarwal, M.D., Ph.D. as Senior V.P., Clinical Development and Steve DeMattos as Senior V.P., Clinical Operations –
April 27, 2021
Arch Oncology Secures $105 Million Series C Financing
– Proceeds to support clinical progress of differentiated anti-CD47 candidate AO-176 for patients with solid tumors and hematologic malignancies –
April 10, 2021
Arch Oncology Presents New Preclinical T-ALL Data on Highly-differentiated Anti-CD47 Antibody AO-176 at AACR 2021
-- Late-breaking presentation highlights preclinical data for AO-176 in T-ALL -- -- Late-breaking presentation highlights preclinical data for AO-176 in T-ALL --
April 07, 2021
Arch Oncology Appoints Laurence Blumberg, M.D. President and CEO
BRISBANE, Calif. and ST. LOUIS, April 07, 2021 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the appointment of Laurence Blumberg, M.D. as President and Chief Executive Off…
March 10, 2021
Arch Oncology Announces Two New Preclinical Data Presentations on Highly Differentiated Anti-CD47 Antibody AO-176 at AACR 2021
-- Two presentations to highlight AO-176’s potential in lymphoma and T-ALL -- BRISBANE, Calif. and ST. LOUIS, March 10, 2021 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced t…
Arch Oncology Blogs
May 24, 2021
A First-in-Human Study of AO-176, a Highly Differentiated Anti-CD47 Antibody, in Patients with Advanced Solid Tumors
Publication: American Society of Clinical Oncology (ASCO). Authors: Howard A. Burris III MD, FACP, FASCO, Alexander I. Spira MD, PhD, FACP, Matthew H. Taylor MD, Oladapo O. Yeku MD, PhD, FACP, Joyce F. Liu MD, Pamela N. Munster MD, Erika P. Hamilton MD, Jacob Stephen Thomas MD, Frances Gatlin , Rich…
February 16, 2021
Oppenheimer’s 31st Annual Healthcare Conference
March 16, 2021, 4:30 – 5:00 pm ET
The post Oppenheimer’s 31st Annual Healthcare Conference appeared first on Arch Oncology.
February 09, 2021
Arch Oncology to Collaborate with Merck on Phase 1/2 Clinical Trial of Anti-CD47 Antibody AO-176 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Select Solid Tumors
BRISBANE, CA and ST. LOUIS, MO, February 9, 2021 – Arch Oncology to Collaborate with Merck on Phase 1/2 Clinical Trial of Anti-CD47 Antibody AO-176 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Select Solid Tumors. With Encouraging Safety and Anti-tumor Activity for AO-176 Monothera…
December 06, 2020
Arch Oncology Presents New Preclinical Data on Highly Differentiated Anti-CD47 Antibody AO-176 at ASH 2020
BRISBANE, CA and ST. LOUIS, MO, December 6, 2020 – Arch Oncology, Inc., a clinical-stage immuno-oncology company Presents New Preclinical Data on Highly Differentiated Anti-CD47 Antibody AO-176 at ASH 2020
The post Arch Oncology Presents New Preclinical Data on Highly Differentiated Anti-CD47 Antib…
November 09, 2020
Arch Oncology to Present New Preclinical Data on Highly Differentiated Anti-CD47 Antibody AO-176 at SITC 2020
BRISBANE, CA and ST. LOUIS, MO, November 9, 2020 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced announced the presentation of new preclinical data on AO-176 at the SITC Annual Meeting 2020.
Th…
October 26, 2020
Stifel 2020 Annual Healthcare Conference
Stifel 2020 Annual Healthcare Conference, November 17, 2020, 4:40 pm ET
The post Stifel 2020 Annual Healthcare Conference appeared first on Arch Oncology.
Arch Oncology Frequently Asked Questions
When was Arch Oncology founded?
Arch Oncology was founded in 2006.
Who are Arch Oncology key executives?
Arch Oncology's key executives are John McKearn, Daniel Pereira and Arun Kashyap.
How many employees does Arch Oncology have?
Arch Oncology has 43 employees.
Who are Arch Oncology competitors?
Competitors of Arch Oncology include Jacobio Pharmaceuticals, Priothera and Tollys.
Where is Arch Oncology headquarters?
Arch Oncology headquarters is located at 2000 Sierra Point Pkwy #700Brisbane, Brisbane.
Where are Arch Oncology offices?
Arch Oncology has offices in Brisbane and St. Louis.
How many offices does Arch Oncology have?
Arch Oncology has 2 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies